MK6482 + lenvatinib / cabozantinib
Categoría
Drugs Multinational Subsidiaries
Tipo de registro
Biotech Sanitaria
Nombre socio
Producto / Servicio
MK6482 + lenvatinib / cabozantinib
Tipo
Biodrugs/ Drugs
Area terapéutica
Oncología
Propiedades/Indicación
MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy.
Fase de desarrollo
P III